Drug intelligence / Profile preview

Amberen

Development stage
Unknown
Lead developer
Alliance Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Amberen is a non-hormonal, multi-ingredient dietary supplement developed for the relief of vasomotor, psychosomatic, and psychological symptoms associated with perimenopause and menopause. Originally developed by Lunada Biomedical (which later became Biogix) and subsequently acquired by Alliance Pharmaceuticals, Amberen is formulated as a proprietary blend of succinate salts (including ammonium, calcium, and magnesium succinates), zinc difumarate, glycine, monosodium L-glutamate, and vitamin E. The supplement is proposed to support cellular energy metabolism and restore hormonal balance by acting on the hypothalamic-pituitary-ovarian axis, potentially stimulating endogenous hormone production (such as estradiol) without introducing exogenous hormones. Clinical trials have evaluated its efficacy in alleviating common menopausal symptoms like hot flashes, night sweats, sleep disturbances, and anxiety.

Brand names
Amberen
Other names
Amberen Advanced Menopause ReliefAmberen MenopauseAmberen Perimenopause
02

Targets

SUCNR1 (Succinate receptor 1)SDH (Mitochondrial electron transport chain complex II)

Beyond the preview

Go deeper on Amberen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amberen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call